Skip to main content
. 2023 Aug 15;9:68. doi: 10.1038/s41523-023-00568-5

Fig. 4. Resistance to olaparib and AZD1775 can be overcome with the addition of STING agonist.

Fig. 4

a, b, d AT3, 4T1ch9 and AT3OVA tumour-bearing mice were treated with the indicated compounds. AT3 and AT3OVA tumour models: 6 mice per treatment group. 4T1ch9 tumour model: 8 mice per treatment group. Data pooled from 2 independent experiments. Data shows mean ± s.d. c AT3 tumour-bearing mice were treated with vehicle, olaparib and/or AZD1775 for 15 days. Tumours and were harvested and analysed via flow cytometry. 6 mice per treatment group. Data shows mean ± s.d. ns: non-significant. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by log-rank (Mantel-Cox) test for survival curves and one-way ANOVA.